Lv44
696 积分 2025-11-14 加入
Feasibility of Bruton’s Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient Perspective
1个月前
已完结
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
1个月前
已完结
Acalabrutinib alleviates metabolic dysfunction–associated steatotic liver disease by regulating bile acid metabolism
1个月前
已完结
The current and future landscape of Bruton’s tyrosine kinase inhibitors in allergy
1个月前
已完结
BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies
1个月前
已完结
BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies
1个月前
已完结
Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors
1个月前
已完结
Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis
1个月前
已完结
Expert opinion on managing adverse reactions associated with acalabrutinib therapy: A Delphi consensus from France
1个月前
已完结
BTK inhibitors: past, present, and future
1个月前
已完结
皖公网安备34019202002308
